Brief: Sernova receives first payment from European Commission's grant to fund a hemophilia therapeutic
16/02/2016 11:02
Feb 16 (Reuters) - Sernova Corp SVA.V : * Receives first payment from the European commission's horizon 2020 grant to fund development of a cell-based hemophilia therapeutic Source text for Eikon urn:newsml:reuters.com:*:nMKW5Zf3ra Further company coverage SVA.V ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints